

Interim Report Q1 2022

Proteins for life

EXPRES²ION
BIOTECHNOLOGIES

Expres²ion Biotech Holding AB
Org. Nr. 559033-3729



Forward-looking statements and disclaimer

This report contains forward-looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward-looking statements. All statements other than statements of historical facts included in this report, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward-looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive

environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Further, certain forward-looking statements are based upon assumptions of future events which may not prove to be accurate. The forward-looking statements in this document speak only as at the date of this report. ExpreS²ion Biotech does not undertake any obligation to update or revise forward-looking statements in this report nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Definitions

“ExpreS²ion Biotech Holding AB” refers to ExpreS²ion Biotech Holding AB with corporate identity number 559033-3729. “The Company” or “ExpreS²ion” refers to the group, i.e. ExpreS²ion Biotech Holding AB and its fully owned operational subsidiary ExpreS²ion Biotechnologies ApS, Denmark.

A word from our CEO

“The year started on a strong note, as we were able to present further positive preclinical proof-of-concept results for our HER2-cVLP breast cancer vaccine in the beginning of January.”

In the first quarter of 2022, ExpreS²ion continued to achieve excellent progress. The year started on a strong note, as we were able to present further positive preclinical proof-of-concept results for our HER2-cVLP breast cancer vaccine in the beginning of January. These results demonstrated that our vaccine candidate ES2B-C001 is able to effectively inhibit and even prevent cancer growth in HER2-tolerant mice, and thus that our vaccine has excellent potential to become a treatment for breast cancer patients who are not responding to the conventionally used HER2-targeting monoclonal antibody trastuzumab. This important preclinical milestone will be followed by results from the remaining on-going animal proof of concept studies later in the first half of 2022.

Furthermore, we had a scientific meeting with the Danish Medicines Agency on our clinical study design for this project, and their feedback was reassuring and constructive for the on-going development. Based on this feedback, we have added an additional preclinical safety study in the first half of 2023, which means that we now aim to file a clinical trial application for our Phase I trial in the second half of 2023 and dose the first human in the first half of 2024. I feel very confident in this updated

development plan, as well as in the overall potential of our HER2-cVLP breast cancer vaccine.

During the quarter, we were also able to announce additional positive results from the ongoing Phase II clinical trial for the ABNCoV2 COVID-19 vaccine, which is being developed as a universal booster vaccine by Bavarian Nordic. The full data from the study confirms that the vaccine increases existing levels of SARS-CoV-2 neutralizing antibodies by 2-40-fold, depending on the initial levels of antibodies, with no serious adverse events reported. Based on this excellent outcome, Bavarian Nordic plans to initiate a Phase III study in the first half of 2022. In May, after the end of the period, another round of additional data from the study was released, and this time for the Omicron variant. We were excited to see that the ABNCoV2 vaccine was demonstrated to boost neutralizing antibody titers also against this variant to levels associated with a high level of protection across both dose groups, 50µg and 100µg. This result is a further testament to the strong and broad immune response induced by the vaccine.

Just after the end of the period, in the beginning of April, we announced the

decision to carry out a fully guaranteed preferential share issue of approximately 73 MSEK. The proceeds will enable us to advance our HER2 breast cancer vaccine project, as well as our other pipeline projects for influenza and malaria, improve our technology platform and also strengthen our strategically important CRO business. We were thrilled to later report a subscription rate of approx. 85 percent for this share issue, which is a really strong outcome considering the current market situation.

I want to thank all old and new shareholders who supported the company by subscribing for shares in this share issue, and I feel certain that we will be able to convert the proceeds into a continued strong news flow also in the coming quarters. 2022 is without doubt becoming another exciting year for ExpreS²ion, as we continue to develop innovative vaccine treatments for some of the most important medical challenges of our time.

Bent U. Frandsen

CEO, ExpreS²ion Biotech Holding AB

About ExpreS²ion

ExpreS²ion Biotechnologies ApS was founded in 2010 on the realisation that to produce the complex proteins needed for biological drugs and vaccines of the future, in a safer and more efficient manner, a new protein expression system would be needed.


The Company developed the ExpreS2 recombinant protein expression platform supporting all phases of drug discovery and R&D as well as GMP manufacturing for clinical studies. With the ExpreS2 platform, the Company enables high-quality production of complex proteins using *Drosophila melanogaster* (fruit fly) S2 cell lines. ExpreS²ion has emerged as a company capable of solving difficult protein challenges and intends to be at the forefront of vaccine development platforms. Since 2019, ExpreS²ion's offering to the biopharmaceutical industry also includes glycol-engineered S2 cell lines under the GlycoX-S2™ brand. This allows for functional modification, e.g., by enhancing immunogenicity or improving pharmacokinetics. The Company sells licenses to use the ExpreS2 platform as a whole or in part to both pharmaceutical companies and research institutions. All ExpreS²ion's pipeline assets incorporate the ExpreS2 technology.

The Company believes that the strengths of the platform include:

1. Significantly less costly and time-consuming than alternative methods, which is an important competitive advantage, considering time-to-market and patent expiry. It also makes the platform particularly valuable for the development of diagnostics and vaccines in epidemic or pandemic situations where speed is of the essence.
2. Generates higher yields, i.e. amount of protein per manufacturing batch, compared to competing systems.
3. Provides homogeneous manufacturing batches, a requirement in pharmaceutical development. The platform includes the Company's patented expression vectors which were developed, among other things, to make it possible for the cells to generate higher yields.
4. Since 2019 the Company's offering to the biopharma sector includes glyco-engineered S2 cell lines under the GlycoX-S2™ brand. This allows for functional modification, e.g. by enhancing immunogenicity or improving pharmacokinetics.

Company structure

Expres²ion has a streamlined company structure. Expres²ion Biotech Holding AB is the Swedish entity listed on Nasdaq First North Growth Market since 2016. Expres²ion Biotechnologies ApS is the operational entity, with offices and labs in the Scion DTU Science park 20 km north of Copenhagen, Denmark, and was established in 2010. AdaptVac ApS is a joint venture established in 2017 together with a group of scientists from the Institute of Immunology and Microbiology at the University of Copenhagen. The scientists own their part of AdaptVac through a joint holding company named NextGen Vaccines ApS.



Business model

Vision and mission of the Company

ExpreS²ion is a biotechnology company that turns complex proteins into tomorrow's vaccines and aims to become a leading player within infectious diseases and cancer. The Company strives to deliver new preventive and therapeutic products that meet some of the gravest global medical needs. The Company aims to achieve this through scientific excellence, a continued focus on academic and industrial collaborations and a profound loyalty to the Company's core skills in protein expression and vaccine development.

Business model

The Company's business model is first and foremost to develop a unique pipeline of preventive and therapeutic vaccine products. In parallel herewith, the Company generates revenue by providing fee-for-service contract research and products within recombinant protein expression, as well as outlicensing the ExpreS² platform to research institutes and pharmaceutical companies which develop biopharmaceutical drugs and vaccines

on their own, or in cooperation with the Company. The Company also sells ExpreS² test kits and reagents for application as research tools or diagnostics. This model generates short term revenue from the contract research organization (CRO) business, while the pharmaceutical products developed using the Company's technology carry potential future royalties, license fees, and milestone payments.

The Company is building its own pipeline of preclinical and later-stage clinical biopharmaceutical drug and vaccine candidates. ExpreS²ion will carry out its own initial research, preclinical and early clinical development work (proof-of-concept) prior to out-licensing. The agreement with Bavarian Nordic in 2020, under which Bavarian Nordic assumes all future development costs for the COVID-19 vaccine program and pay certain milestones and royalties, subject to external funding, is according to the Company the first example of validated ability to develop new preventive and therapeutic products that meet some of the gravest medical needs.

The Company believes that the combination of an inhouse pipeline of biopharmaceutical drug and vaccine candidates, while maintaining a revenue generating CRO business, puts the Company in a good position to balance risk and return and create value for its shareholders.

Strategy and growth

ExpreS²ion aims to develop the pipeline further by adding additional projects while continuing preclinical and early clinical development work on existing projects. The Company targets human Proof-of-Concept in order to maximize high-value partnerships for further development, but acknowledge that earlier partnering is also an option for progressing pipeline projects. The Company also aims to improve the technology platform further to ensure competitiveness. This is done by improving the ExpreS² system, potentially adding relevant compatible technologies, and continuing to sell licenses for the use of the ExpreS² platform.

See Business model on next page →



ExpreS2 Platform for Protein Expression:

+500 different proteins have been produced with the ExpreS2 platform, while posting a success rate exceeding 90% across +100 clients and partners.



Novel Pipeline Development

Independent

Fully-owned development of novel protein therapeutics and vaccines

After human PoC, targeting partner externally for further development

Collaboration

Partner with leading research organizations to source and develop novel programs

Potential to fully acquire programs for independent development

**Significant upside potential:
Intermediate/long-term**

Contract Research Organization (CRO)



Services

Early-stage R&D for leading academic, research, and biotech organizations

Protein feasibility, delivery, and transfer to GMP production

Licensing & Kit Sales

Fully out-license rights to ExpreS2 technology

Sell test kits and reagents for research or diagnostic applications

**Revenue-generating business:
Current and long-term payments**

Partners

Broad Customer and Collaborator Base

With over 100 currently active or former academic and industrial service and license contracts, the Company has built a large network in the international research community since its inception in 2010. Furthermore, the Company is currently a part of an international research consortia which together has been granted more than an estimated EUR 40 million of non-dilutive public funding. The Company also sells licenses to use the ExpreS2 platform as a whole or in part, thus allowing its clients to participate in or be entirely responsible for the development of the required proteins. The Company sells ExpreS2 test kits and reagents for application as research tools or diagnostics. The Company may also enter into agreements in which the client accepts a quotation and is charged for the development, production and delivery of research grade proteins, using the ExpreS2 platform.

The Company services both pharmaceutical companies and research institutions. The ExpreS2 platform is equally suited for academic research, analytics and commercial drug development, both in vaccines and other biopharma fields. The Company's clients are not limited to any geographic area and are located all over the world. Since its foundation in 2010, the Company has worked with more than 100 clients and partners. The agreements with these clients, which in many cases are world-leading universities, research institutions and pharmaceutical companies, have generated significant revenues for the Company over the years. It currently has more than ten major clients. For instance, the Company has out-licensed the ExpreS2 platform for research to Hoffman-La Roche, Imperial College London and Francis Crick Institute among others, and outlicensed the platform for clinical development to the University of Copenhagen and the Jenner Institute of the University of Oxford, among others.



+100

Since its foundation in 2010, the Company has worked with more than 100 clients and partners



Academics

- Boston Children's Hospital
- Cancer Research, UK
- Harvard Medical School
- Imperial College London
- The Jenner Institute
- Sir William Dunn School of Pathology
- Statens Serum Institute
- Technical University of Denmark (DTU)
- University of Copenhagen
- Department of Biochemistry, University of Oxford



Big Pharma





- Eli Lilly
- Janssen, Pharmaceutical companies of Johnson & Johnson
- Novartis
- Roche
- Servier



Small and medium-sized enterprises, contract manufacturing organizations, diagnostics and retailers

- AGC Biologics
- Genlbet Biopharmaceuticals
- Idorsia
- Integrated biotherapeutics
- Intravacc
- Virion\Serion; SERION Diagnostics

Pipeline

DISEASE	Project / Target	Discovery	Pre-clinical Pharmacology	cGMP / Tox	Phase 1	Phase 2	Phase 3	Market potential
Corona virus	 ABNCoV2/SARS-CoV-2 cVLP							> 100 billion EUR
Breast cancer	 ES2B-C001/Her2 cVLP							> 15 billion EUR
Influenza	 Hemagglutinin							> 4 billion EUR
Malaria								> 0.6 billion EUR
I: Blood	RH5							
II: Blood	RH5-VLP							
III: Transmission	Pfs 48/45							
IV: Placental	VAR2CSA							
V: Blood	CYRPA complex							

As of May 2022

Pipeline



CORONAVIRUS/COVID-19

ExpreS²ion and its associated company AdaptVac have been engaged in the development of a unique capsid virus-like particle (cVLP) COVID-19 vaccine, partly sponsored through a Horizon 2020 EU grant award to the PREVENT-nCoV consortium to rapidly advance the vaccine candidate against COVID-19 into the clinical stage. The candidate vaccine is a cVLP applying ExpreS²-produced SARS-CoV-2 antigens, thereby creating a powerful immunogenic vaccine. In July 2020, AdaptVac and Bavarian Nordic, a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving

vaccines, entered into a license agreement providing Bavarian Nordic the global commercialization rights to the proprietary capsid virus like particle based SARS-CoV-2 subunit vaccine, designated ABNCov2. For application of our proprietary protein production system ExpreS², ExpreS²ion and AdaptVac have also entered into a license agreement for this project.

In addition to ExpreS²ion and AdaptVac, the PREVENT-nCoV consortium members are Leiden University Medical Center (LUMC), Institute for Tropical Medicine (ITM) at University of Tübingen, The Department of Immunology and Microbiology (ISIM) at University of Copenhagen, the Laboratory of Virology at Wageningen University, and Radboud University Medical Center. We announced the first headline results of the clinical Phase I/IIa in August 2021 and demonstrated positive safety and efficacy outcomes. Bavarian Nordic is currently running a Phase II study to determine the vaccine's potential as a universal booster. Preliminary results in December 2021 demonstrated a strong boosting effect for all variants tested and confirmed the vaccine's excellent profile as a non-adjuvanted universal COVID-19 booster vaccine.

Additional positive Phase II results were presented in February 2022. The full study data confirms that existing levels of SARS-

CoV-2 neutralizing antibodies increased by 2-40-fold, depending on the initial levels of antibodies, with no serious adverse events reported. Based on this excellent outcome, Bavarian Nordic plans to initiate a Phase III study in the first half of 2022.



BREAST CANCER

Breast cancer is a widespread oncology indication affecting more than 1.3 million people worldwide annually, resulting in more than 450,000 deaths (Tao, 2015: www.ncbi.nlm.nih.gov/pubmed/25543329). The most common treatment today is based on monoclonal antibodies, where the dominating therapies Herceptin (trastuzumab) and Perjeta (pertuzumab) generate annual global sales of USD 7 billion.

The target product profile of our lead breast cancer project, ES2B-C001 (HER2-cVLP), is tailored to be highly

competitive both in terms of cost and efficacy, thus aiming at a significant market share.

In February 2021, ExpreS²ion signed a final patent license agreement with AdaptVac whereby ExpreS²ion exclusively licensed in AV001 (renamed ES2B-C001). This gives ExpreS²ion full control over and responsibility for driving this valuable asset forward, hereby realising the very significant value of this project. At the end of 2021, ExpreS²ion's candidate demonstrated strong tumor-growth inhibiting effect in a mice models, thus reaching an important pre-clinical milestone ahead of schedule. Additionally, anti-HER2 antibodies from these studies were found to effectively inhibit tumor growth in human cancer cells. The candidate also demonstrated proof-of-concept in HER2-transgenic preventive as well as therapeutic tumor mice models, thus reaching a further important pre-clinical milestone.

Based on feedback from the Danish Medicines Agency (DKMA), ExpreS²ion intends to conduct additional preclinical safety studying, which will increase the robustness of the project's preclinical data. Consequently, the Company is now aiming to file the clinical trial application for the Phase I trial in the second half of 2023, with the aim of dosing first in human in the first half of 2024.



INFLUENZA

The international next-generation influenza vaccine consortium INDIGO, led by the University of Amsterdam with ExpreS²ion as a participating member, is developing a next-generation influenza vaccine in a large collaboration between public and private R&D organisations from the EU, India, and the United States. The project has been awarded a 10 MEUR Horizon 2020 grant from the EU, of which ExpreS²ion's participation was directly awarded 0.6 MEUR.

The INDIGO consortium plans to carry out the preclinical and clinical development of the project, which contains two novel influenza vaccine concepts, including the application of a novel potent adjuvant by LiteVax BV, the Netherlands, as well as the use of the ExpreS² platform for antigen production by ExpreS²ion. The aim is to create an influenza vaccine that meets the requirements of global vaccination, i.e. to achieve <10% instead of 60% non-responders, combined with a lower

manufacturing cost and better accessibility.



MALARIA PROJECTS

Malaria I

Blood stage (RH5-1)

Jenner Institute of the University of Oxford is developing the blood-stage Plasmodium falciparum malaria antigen RH5.1 with ExpreS²ion as a collaboration partner. The RH5.1 antigen is produced in ExpreS²ion's ExpreS² platform.

Malaria II

Blood stage (RH5-2)

With the aim to further improve efficacy, the Jenner Institute of the University of Oxford is developing a second-generation RH5 vaccine, RH5.2, in the ExpreS² platform. RH5.2 has been engineered to retain regions important for red blood cell recognition, which are targeted by neutralising antibodies. Additionally, the RH5.2 protein will be

displayed on the surface of a hepatitis B derived virus-like particle (VLP) in order to maximise the induction of high titre antibodies. The project is funded by the Wellcome Trust.

Malaria III

Transmission (Pfs48/45)

The goal for a transmission-blocking vaccine is to prevent the transfer to mosquitos feeding on persons infected with malaria, thus effectively hindering further spread of the disease. Thereby a transmission-blocking vaccine does not give direct protection from the disease, but it stops the disease from spreading and could therefore lead to eradication of malaria. During the last decade, the inability to produce the full-length Pfs48/45 antigen has been a major roadblock for researchers aiming to create a transmission-blocking malaria vaccine. However, this challenge was overcome by ExpreS²ion and Jenner Institute at the University of Oxford.

This vaccine is developed by the Horizon 2020-funded OptiMalVax grant consortium, led by Jenner Institute at the University of Oxford with ExpreS²ion as a member. The objective of the consortium is to create a combination malaria vaccine, and its clinical program will include trials to assess the pre-erythrocytic, blood-stage and mosquito-stage components of the combination vaccine, including this transmission vaccine.

Malaria IV

Placental (VAR2CSA)

ExpreS²ion is a part of the PlacMalVac project that started in 2013 as an international consortium project with the aim to develop a vaccine against placental malaria. The project is based on the antigen VAR2CSA, which enable parasite accumulation in the placenta and was discovered by Professor Ali Salanti and others at the University of Copenhagen.

Malaria V

Blood-stage (PfRipr complex)

An international research team, including scientists from ExpreS²ion and led by the Walter and Eliza Hall Institute of Medical Research (WEHI), is developing a next generation malaria vaccine that is targeting a recently discovered molecular 'key' that the deadly malaria parasite uses to enter human blood cells. The malaria 'key' was first described in a Nature article, published December 2018 from the group. It is a complex of three parasite proteins called Rh5, CyRPA and Ripr, where the three proteins work together to unlock and enter the cell. This central role in the infection of human blood cells makes the complex a new and promising target for vaccine development. The vaccine is based on a patent co-owned by WEHI and ExpreS²ion.

Significant events

First quarter of 2022

On January 4, ExpreS²ion announced that the capsid virus-like particle (cVLP) HER2-breast cancer vaccine candidate ES2B-C001 has demonstrated proof-of-concept also in HER2-transgenic preventive as well as therapeutic tumor mice models. The vaccine has thus reached a further important pre-clinical milestone.

On February 8, ExpreS²ion announced constructive feedback from its scientific advice meeting pertaining to the therapeutic breast cancer vaccine candidate, ES2B-C001, with the Danish Medicines Agency ("DKMA"). Based on this feedback, ExpreS²ion plans to conduct an additional preclinical safety study in the first half of 2023, which will increase the robustness of the project's preclinical data. Consequently, the Company is now aiming to file the clinical trial application for the Phase I trial in the second half of 2023, with the aim of dosing first in human in the first half of 2024.

On February 24, ExpreS²ion announced its financial results for the fourth quarter and full-year 2021.

On February 28, ExpreS²ion announced that additional positive results for the ABNCoV2 vaccine, that is being developed as a universal booster vaccine, has been presented from the Phase II clinical trial conducted by Bavarian Nordic. The full

study data confirmed that existing levels of SARS-CoV-2 neutralizing antibodies increased by 2-40-fold, depending on the initial levels of antibodies, with no serious adverse events reported. Based on this excellent outcome, Bavarian Nordic plans to initiate a Phase III study in the first half of 2022.

Subsequent events

On April 6, ExpreS²ion announced that the Board of Directors of ExpreS²ion Biotech Holding AB (publ) ("ExpreS²ion" or the "Company"), on the basis of the authorization from the Annual General Meeting on 26 May 2021, resolved to carry out a new share issue with preferential rights for the Company's existing shareholders (the "Rights Issue"). The Rights Issue encompasses 5,841,273 shares at a subscription price of SEK 12.50. The Rights Issue is fully covered by subscription undertakings made by certain existing shareholders and guarantee commitments from existing shareholders and new investors. The Company will upon full subscription of the Rights Issue receive gross proceeds of approximately SEK 73 million. The expected net proceeds from the Rights Issue will be used as to advance the breast cancer vaccine candidate ES2B-C001 to completion of the preclinical safety studies, advance other pipeline development projects, including within Influenza and Malaria, and support the strategic CRO

business and invest in core technologies and IP to strengthen competitive edge.

On April 13, ExpreS²ion announced that the prospectus related to the Rights Issue announced on April 6 had been published on the Company's website and was available in Swedish and English.

On May 4, ExpreS²ion announced the publication of the 2021 Annual Report.

On May 5, ExpreS²ion announced that additional positive results for the ABNCoV2 vaccine, that is being developed as a universal booster vaccine, had been reported from the Phase II clinical trial conducted by Bavarian Nordic. The new study data demonstrated a significant boost to the neutralizing antibodies against the Omicron variant in the majority of subjects with a fold increase in the same range as previously reported for the original Wuhan SARS-CoV2 variant. Bavarian Nordic continued to plan for rapid initiation of a Phase III study.





On May 5, ExpreS²ion announced the final outcome of the Rights Issue which showed that a total of 4,966,355 new shares had been subscribed for, corresponding to approximately 85 percent. The remaining 874,901 new shares, approximately 15.0 percent, had been subscribed for through guarantee undertakings. The Company will

receive proceeds of approximately SEK 73 million before deduction of costs attributable to the Rights Issue.

On May 25, ExpreS²ion announced that the capsid virus-like particle (cVLP) HER2-breast cancer vaccine candidate ES2B-C001 has demonstrated additional positive proof-of-concept also in a metastatic outgrowth therapeutic tumour mice model. These data support the already established preclinical proof-of-concept results announced in December 2021 and January 2022.

On May 25, ExpreS²ion held the 2021 Annual General Meeting (AGM), during which resolutions were passed related to the adoption of the income statement and balance sheet, allocation of profit, discharge from liability, election of the Board of Directors, Auditor and remuneration, security issuance authorization, and incentive programs. The AGM was carried out through advance voting (postal voting) pursuant to temporary legislation.

Advancing towards key catalysts

	2022	2023	2024+
 <p>CORONAVIRUS/ COVID-19 ABNCoV2</p>	<p>✓</p> <p>BN Phase II trial readout H1</p> <p>BN Phase III trial initiation H1</p> <p>BN Phase III initial readout H2</p>	<p>BN ready for market launch (subject to regulatory approval)</p>	
 <p>BREAST CANCER ES2B-C001</p>	<p>✓</p> <p>Preclinical animal proof-of-concept results H1</p> <p>GMP manufacturing batch</p>	<p>Preclinical safety studies readout</p> <p>Filing of clinical trial application H2</p>	<p>Initiation of first human clinical trial</p> <p>Outlicensing window opens pending human data</p>
 <p>INFLUENZA</p>	<p>Advance/support further development of one or more candidates</p>		
 <p>MALARIA</p>	<p>Pfs 48/45 phase I trial initiation</p>	<p>RH5-VLP phase I initiation</p> <p>RH5 phase I trial readout H2</p>	

Note: Timeline for ABNCoV2 is based on Bavarian Nordic's communicated timeline and is subject to potential revision.

Summary of Q1 interim results



First Quarter (January – March 2022)

- Operating income amounted to 2,078 (1,931) KSEK.
- Profit/loss after financial items amounted to -14,844 (-12,128) KSEK.
- Profit/loss for the period amounted to -13,836 (-11,155) KSEK.
- Net income per share* amounted to -0.44 (-0.40) SEK.

Key financials

SEK '000s	Q1 2022	Q1 2021	% Change
Operating income	2,078	1,931	8%
Profit/loss after financial items	-14,844	-12,128	22%
Profit/loss for the period	-13,836	-11,155	24%
Earnings per share*	-0.44	-0.40	10%
Cash balance, end of period	39,563	82,807	-52%
Cash balance including SKAT balance, end of period**	124,678	82,807	51%
Total assets	140,035	151,956	-8%
Equity/asset ratio (%)***	94%	92%	1%

Figures in parenthesis are the numbers from the same period in 2021.

*The Group's net income per share: The net income for the period divided with the average number of shares for the period. For the period January to March 2022, the average number of shares amounted to 31,153,456. As of 31/03/2022, the total number of shares in ExpreS²ion Biotech Holding AB was 31,153,456.

**In Q4 2021 the Company decided to store cash in its account with the Danish tax authority (SKAT), where no interest is charged. See callout on next page for more information.

***Equity ratio: Shareholder's equity divided by total capital.

Financial overview

Development in figures for Q1 2022 / Year-to-date

Operating income

Total operating income during the first quarter of 2022 amounted to KSEK 2,078 (1,931), which was 8% higher compared to the same period last year. Thus far in 2022, operating income was almost entirely driven by net sales from client projects, licenses and purchases from our web store, whereas grant income was minimal.

Profit/loss for the period

The net loss for the first quarter of 2022 amounted to KSEK -13,836 (-11,155). The lower result is almost entirely due to increased personnel costs, which in 2022's first quarter increased due to higher headcount and increases in non-cash incentive-based compensation. Partially offsetting are (1) reduction in costs attributed to raw materials, (2) lower research development costs as 2021's first quarter included the exercise of the Company's option to license the ES2B-C001 breast cancer vaccine, and (3) lower depreciation.

Cash and cash equivalents

As of March 31, 2022, ExpreS²ion's cash and cash equivalents amounted to KSEK 39,563 (82,807). Including the SEK 85.1 million in the Company's account with the Danish tax authority (SKAT), the Company had SEK 124.7 million available to fund its ongoing operations. During the quarter, cash (including the SKAT balance) decreased by SEK 14.1 million, primarily reflecting an operating loss of SEK 14.6 million, which was partially offset by adjustments for non-cash items (SEK 3.5 million), specifically vesting of non-cash incentive-based compensation..

Cash and the Danish tax authority's payout limit

On May 7, 2020, the Danish tax authority (SKAT) increased the payout limit for SKAT accounts to DKK 100 billion due to the extraordinary COVID-19 situation. On February 1, 2022, this limit changed to DKK 350 million. SKAT allows companies to store up to that limit in their SKAT account where the balance does not incur negative interest. After consultation with SKAT, the Company's bank and the Company's advisors, ExpreS²ion decided to store a portion of its cash in its SKAT account, thereby significantly reducing interest expense. At the end of Q1 2022, the Company had SEK 85.1 million in its SKAT account. Each month the company considers its cash need in the coming months and adjusts the payout limit. Any amount in the account beyond the limit is transferred to the Company's bank account in less than two weeks. The balance with SKAT is recorded within the Company's other short-term investments.

This report has been prepared using the same accounting principles as used for the 2021 Annual report published 4 May 2022. All figures refer to group results unless stated otherwise. Figures in parenthesis are from the same period in 2021.

Income statement – group

KSEK	Q1 2022	Q1 2021	% change	FY 2021
Operating income				
Net sales	2,033	1,704	19%	12,234
Other operating income	45	227	-80%	1,496
Total operating income	2,078	1,931	8%	13,730
Operating costs				
Raw materials & consumables	-949	-2,632	-64%	-7,513
Research & development costs	-1,585	-2,896	-45%	-9,815
Other external costs	-3,241	-3,343	-3%	-3,516
Personnel costs	-10,632	-4,263	149%	-32,374
Depreciation of tangible & intangible fixed assets	-316	-742	-57%	-1,809
Other operating expenses	0	0	n/a	-7,099
Total operating costs	-16,723	-13,876	21%	-62,126
Operating profit/loss	-14,645	-11,945	23%	-48,396
Result from financial investments				
Result in associated companies	0	207	-100%	671
Interest expense & similar items	-199	-391	-49%	209
Total result from financial investments	-199	-184	8%	880
Profit/loss after financial items	-14,844	-12,129	22%	-47,516
Income tax on the result for the period	1,008	973	4%	3,591
Profit/loss for the period	-13,836	-11,156	24%	-43,925

Balance sheet – group

KSEK	Q1 2022	YE 2021	% change	Q1 2021
Assets				
Concessions, patents, licenses, trademarks and similar intellectual rights	3,068	3,141	-2%	3,601
Goodwill	0	0	n/a	50
Total non-current intangible assets	3,068	3,141	-2%	3,651
Plants and machinery	1,037	1,209	-14%	1,225
Total non-current tangible assets	1,037	1,209	-14%	1,225
Interest in associated companies	24	23	4%	23
Other long-term receivables	1,188	1,119	6%	1,078
Total non-current financial assets	1,212	1,142	6%	1,101
Total non-current assets	5,317	5,492	-3%	5,977
Accounts receivable	776	1,623	-52%	599
Tax receivables	4,456	3,470	28%	3,750
Other receivables	3,050	2,012	52%	4,132
Prepaid expenses and accrued income	1,758	479	267%	818
Total receivables	10,040	7,584	32%	9,299
Other short-term investments	85,115	101,769	-16%	0
Total short-term investments	85,115	101,769	-16%	0
Cash and bank	39,563	37,111	7%	82,807
Total current assets	134,718	146,464	-8%	92,106
TOTAL ASSETS	140,035	151,956	-8%	98,083

KSEK	Q1 2022	YE 2021	% change	Q1 2021
Equity and liabilities				
Share capital	3,461	3,461	0%	3,068
Other capital contributions	226,657	266,243	-15%	93,489
Other equity including net loss for the period	-98,790	-129,358	-24%	-11,323
Total equity	131,329	140,347	-6%	85,234
Provision for taxes	632	671	-6%	761
Total provisions	632	671	-6%	761
Other long-term liabilities	3,077	3,477	-11%	4,887
Total long-term liabilities	3,077	3,477	-11%	4,887
Liabilities to credit institutions	1,863	1,918	-3%	1,927
Accounts payable	106	1,685	-94%	1,773
Other liabilities	3,028	3,858	-22%	3,501
Total short-term liabilities	4,997	7,461	-33%	7,201
TOTAL EQUITY AND LIABILITIES	140,035	151,956	-8%	98,083

Note: Cash and bank

At the end of Q1 2022, the Company had SEK 85.1 million in its SKAT account, shown in other short-term investments. When combined with cash and bank, the Company had SEK 124.7 million available to fund operations.

See callout on page 15 for more information.

Changes in equity – group

FY 2021

KSEK	Other equity			Total equity
	Share capital	Other capital contributions	including net profit for the period	
Opening balance as of January 1st, 2021	3,067	178,042	-86,561	94,548
Issuance of new shares	394	82,910		83,304
Issuing expenses		-6,778		-6,778
Vesting of share-based compensation		11,756		11,756
Exchange difference for the period			1,442	1,442
Profit-loss for the period			-43,925	-43,925
Total equity as of December 31st, 2021	3,461	265,931	-129,045	140,347

Q1 2022

KSEK	Other equity			Total equity
	Share capital	Other capital contributions	including net profit for the period	
Opening balance as of January 1st, 2022	3,461	265,931	-129,045	140,347
Vesting of share-based compensation		3,230		3,230
Exchange difference for the period			1,587	1,587
Profit-loss for the period			-13,836	-13,836
Total equity as of March 31st, 2022	3,461	269,161	-141,294	131,328

Cash flow statement – group

KSEK	Q1 2022	Q1 2021	% change	FY 2021
Operating profit/loss	-14,644	-11,945	23%	-48,396
Adjustments for items not included in the cash flow	3,546	909	290%	13,486
Interest paid	-144	-393	-63%	-1,194
Income tax received	1	-3	-133%	2,795
Cash flow from operating activities before changes in working capital	-11,240	-11,432	-2%	-33,309
Decrease(+)/increase(-) of current receivables	-1,491	-2,717	-45%	-1,350
Decrease(+)/increase(-) of current liabilities	-2,498	-11,235	-78%	-10,988
Cash flow from operating activities	-15,230	-25,384	-40%	-45,646
Investments in associated companies	0	218	-100%	682
Investments in intangible non-current assets	0	0	n/a	45
Investments in tangible non-current assets	-18	-120	-85%	-715
Other investing activities	17,976	0	n/a	-100,933
Cash flow from investing activities	17,958	98	n/a	-100,921
Leasing agreement	-161	-154	5%	-621
Loans	-442	-330	34%	-1,361
Issuance of new shares	0	0	n/a	83,304
Costs of issuing shares	0	0	n/a	-6,778
Cash flow from financing activities	-603	-484	25%	74,545
Cash flow for the period	2,125	-25,770	-108%	-72,023
Cash and cash equivalents at the beginning of the period	37,111	106,832	-65%	106,832
Exchange difference cash and cash equivalents	327	1,744	-81%	2,302
Cash and cash equivalents at the end of the period	39,563	82,806	-52%	37,111

Note: Cash and cash equivalents at the end of the period

At the end of Q1 2022, the Company had SEK 85.1 million in its SKAT account. When combined with cash, the Company had SEK 124.7 million available to fund operations. The transfers from SKAT are presented in "Other investment activities."

See callout on page 15 for more information.

Income statement – parent

KSEK	Q1 2022	Q1 2021	% change	FY 2021
Operating income				
Net sales	0	0	n/a	368
Total operating income	0	0	n/a	368
Operating costs				
Other external costs	-489	-426	15%	-4,501
Personnel costs	-616	-50	1132%	-2,670
Total operating costs	-1,105	-476	132%	-7,171
Operating profit/loss	-1,105	-476	132%	-6,803
Result from financial investments				
Other interest income & similar items	0	0	n/a	1,015
Interest expense & similar items	-26	-119	-78%	-181
Total result from financial investments	-26	-119	-78%	834
Profit/loss after financial items	-1,131	-595	90%	-5,969
Income tax on the result for the period	0	0	n/a	0
Profit/loss for the period	-1,131	-595	90%	-5,969

Balance sheet – parent

KSEK	Q1 2022	YE 2021	% change	Q1 2021
Assets				
Shares in group companies	250,290	247,563	1%	165,887
Total financial non-current assets	250,290	247,563	1%	165,887
Total non-current assets	250,290	247,563	1%	165,887
Tax receivables	18	18	0%	36
Other receivables	383	179	114%	148
Prepaid expenses and accrued income	876	86	919%	60
Total receivables	1,277	283	351%	244
Cash and bank	5,253	5,220	1%	5,329
Total current assets	6,530	5,503	19%	5,573
TOTAL ASSETS	256,820	253,066	1%	171,460

KSEK	Q1 2022	YE 2021	% change	Q1 2021
Equity and liabilities				
Share capital	3,461	3,461	0%	3,068
Restricted equity	3,461	3,461	0%	3,068
Share premium fund and retained earnings	251,442	254,180	-1%	166,460
Profit/loss for the period	-1,131	-5,969	-81%	-595
Unrestricted equity	250,311	248,211	1%	165,865
Total equity	253,772	251,672	1%	168,933
Payables to group companies	2,312	790	193%	2,242
Other liabilities	736	604	22%	285
Total short-term liabilities	3,048	1,394	119%	2,527
TOTAL EQUITY AND LIABILITIES	256,820	253,066	1%	171,460

Changes in equity – parent

FY 2021

KSEK	Share capital	Other capital contributions	Other equity including net profit for the period	Total equity
Opening balance as of January 1st, 2021	3,067	171,502	-5,210	169,359
Issuance of new shares	394	82,910		83,304
Issuing expenses		-6,778		-6,778
Vesting of share-based compensation		11,756		11,756
Profit-loss for the period			-5,969	-5,969
Total equity as of December 31st, 2021	3,461	259,390	-11,179	251,672

Q1 2022

KSEK	Share capital	Other capital contributions	including net profit for the period	Total equity
Opening balance as of January 1st, 2022	3,461	259,390	-11,179	251,672
Vesting of share-based compensation		3,230		3,230
Profit-loss for the period			-1,131	-1,131
Total equity as of March 31st, 2022	3,461	262,620	-12,309	253,772

Shareholder information

ExpreS²ion Biotech Holding AB's share was listed at Nasdaq First North Growth Market on July 29, 2016. The trading name of the share is EXPRS2 and the ISIN-code is SE0008348262. As of March 31, 2022, the number of shares in ExpreS²ion Biotech Holding AB amounted to 31,153,456. The average amount of shares in the first quarter of 2022 amounted to 31,153,456. The Company has one class of shares. Each share carries equal rights to share in the Company's assets and earnings.

Certified Advisor

Svensk Kapitalmarknadsgranskning AB

Email: ca@skmg.se

Phone: +46 11 32 30 732

Web: www.skmg.se

List of largest shareholders

Name	Number of shares held	Share of votes and capital
Summary, shareholders over 5%	0	0.00%
Remaining shareholders under 5%	31,153,456	100.00%
Total March 31, 2021	31,153,456	100.00%

Warrants

As of March 31st, 2021, the Company had three series of warrants issued, all of which are part of incentive programs. These series are identified as T02, T06 and T07.

T02 (2019/2022)


On May 23, 2019, the Annual General Meeting resolved to implement an incentive program for all employees and issue a maximum of 680,100 warrants, of which 612,084 were subscribed for and allocated to the employees.

T06 (2020/2024)

On September 23, 2020, the Extraordinary General Meeting resolved to implement an incentive program for management and key persons and issue a maximum of 1,000,000 warrants. All warrants were subscribed for by the Company's subsidiary Expres²ion Biotechnologies ApS. 998,000 warrants have subsequently been transferred to selected employees.

T07 (2021/2024)

On May 26, 2021, the Annual General Meeting resolved to implement an incentive program for senior executives, employees and other key persons not included in the T06 program, and issue a maximum of 1,050,000 warrants, of which 770,000 were subscribed for and allocated to the employees as of the publication of this report. All warrants will be subscribed for by the Company's subsidiary Expres²ion Biotechnologies ApS.



Other matters

Employees

As of March 31, 2022, there were a total of 29 employees, corresponding to 26 full-time equivalents (FTE's).

Operational risks and uncertainties

The risks and uncertainties that Expres2ion's operations are exposed to are summarized in terms of pharmaceutical development, competition, technology development, patents, government requirements, capital requirements, currencies, and interest rates. During the current period, no significant changes regarding risk or uncertainty factors have occurred. For more detailed reporting of risks and uncertainties refer to the Company's annual report for the fiscal year of 2021.

Auditor review

This interim report has not been formally reviewed by the Company's auditor.

Accounting principles

Expres2ion Biotech Holding AB applies the Swedish Annual Accounts Act and Swedish Accounting Standards Board's general standard BFNAR 2012:1 (K3) when preparing its financial statements.

For more information, please contact

Bent U. Frandsen, CEO

Telephone: +45 4256 6869

Email: buf@expres2ionbio.com

Keith Alexander, CFO

Telephone: +45 5131 8147

Email: ka@expres2ionbio.com



Financial calendar

August 18, 2022

Half-year report, 2022

November 17, 2022

Q3 report, 2022

February 9, 2023

Full-year report, 2022

Declaration of The Board of Directors and CEO

The Board of Directors and CEO assure that the interim report presents a true and fair view of ExpreS²ion Biotech Holding AB's business, operations, position and results.

Hørsholm, Denmark


May 31, 2022

ExpreS²ion Biotech Holding AB

c/o Mindpark, Rönnowsgatan 8c, S-252 25 Helsingborg

Board of Directors and CEO





Expres²ion Biotech Holding AB c/o
Mindpark
Rönnowsgatan 8c
S-252 25 Helsingborg
www.expres2ionbio.com